Form 4: Neurocrine Biosciences Executive Ingrid Delaet Reports Stock Transactions

Ingrid Delaet, Chief Regulatory Officer of Neurocrine Biosciences, reports the exercise of stock options and subsequent sale of shares under a pre-arranged 10b5-1 trading plan.

Summary

• Ingrid Delaet, Chief Regulatory Officer of Neurocrine Biosciences, filed a Form 4 detailing changes in beneficial ownership of the company's stock.
• On February 28, 2024, Delaet exercised non-qualified stock options to acquire 6,544 shares of common stock at a price of $79.02 per share.
• Simultaneously, Delaet sold 6,544 shares of common stock at weighted average prices of $135.6414 and $134.62, and $136 per share.
• On February 29, 2024, Delaet exercised non-qualified stock options to acquire 273 shares of common stock at a price of $79.02 per share.
• Delaet also sold 273 shares of common stock at a weighted average price of $135.51 per share.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on November 29, 2023.
• Following these transactions, Delaet directly owns 7,507 shares of Neurocrine Biosciences common stock and 5,444 non-qualified stock options.

Sentiment

Score: 5

Explanation: The document reflects routine executive stock transactions under a pre-arranged plan, indicating a neutral sentiment.

Industry Context

Executive stock transactions are common and closely monitored, especially in the pharmaceutical industry, to gauge executive sentiment and ensure compliance with insider trading regulations. The use of 10b5-1 plans is a standard practice to allow insiders to sell shares without being accused of acting on non-public information.

Comparison to Industry Standards

• Executive compensation practices, including stock options and trading plans, are common across the biotechnology and pharmaceutical industries.
• Companies like Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) also utilize stock options as part of their executive compensation packages.
• The vesting schedules and exercise prices are generally aligned with industry norms to incentivize long-term performance.
• The use of Rule 10b5-1 trading plans is a standard practice among executives in publicly traded companies to manage their stock holdings while avoiding insider trading concerns.

Stakeholder Impact

• The transactions may have a minor impact on shareholders, as they reflect insider selling activity.
• However, the existence of a 10b5-1 plan suggests that these sales are pre-planned and not necessarily indicative of the executive's view of the company's future prospects.

Key Dates